Open access
Open access
Powered by Google Translator Translator

Hepatology

Guidelines | Management of ascites in liver disease

31 May, 2023 | 14:08h | UTC

Asia–Pacific association for study of liver guidelines on management of ascites in liver disease – Hepatology International

 

AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

30 May, 2023 | 11:51h | UTC

AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma – Hepatology

 

Liver cystic echinococcosis: a parasitic review

25 May, 2023 | 11:19h | UTC

Liver cystic echinococcosis: a parasitic review – Therapeutic Advances in Infectious Disease

 

RCT | Prophylactic antibiotics show no statistically significant survival improvement in severe alcohol-related hepatitis

15 May, 2023 | 13:21h | UTC

Summary: This multicenter, randomized, double-blind clinical trial aimed to determine the efficacy of amoxicillin-clavulanate combined with prednisolone compared to placebo combined with prednisolone on mortality in patients hospitalized with severe alcohol-related hepatitis. The study involved 284 patients from 25 centers in France and Belgium with biopsy-proven severe alcohol-related hepatitis, who were followed up for 180 days.

The primary outcome was all-cause mortality at 60 days, while secondary outcomes included mortality at 90 and 180 days, infection rates, hepatorenal syndrome, and changes in Model for End-stage Liver Disease (MELD) and Lille scores. The results showed no statistically significant difference in 60-day mortality between the two groups, with 17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group. However, infection rates at 60 days were significantly lower in the amoxicillin-clavulanate group compared to the placebo group.

It is worth noting that the study may have been underpowered, as the absolute risk difference of 4% did not achieve statistical significance. In conclusion, the combination of amoxicillin-clavulanate and prednisolone did not show a statistically significant improvement in 2-month survival in patients hospitalized with severe alcohol-related hepatitis compared to prednisolone alone. These findings do not support the use of prophylactic antibiotics to improve survival in this patient population, but the potential underpowered nature of the study should be considered.

Article: Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Review | Heart failure and liver disease: cardiohepatic interactions

15 May, 2023 | 13:06h | UTC

Heart Failure and Liver Disease: Cardiohepatic Interactions – JACC: Heart Failure

 

Review | Nonalcoholic fatty liver disease from a primary care perspective

15 May, 2023 | 12:57h | UTC

Nonalcoholic fatty liver disease from a primary care perspective – Diabetes, Obesity and Metabolism

 

Recent advances in the management of primary sclerosing cholangitis

11 May, 2023 | 11:45h | UTC

Recent Advances in the Management of Primary Sclerosing Cholangitis – Clinical Gastroenterology and Hepatology

Related:

AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis – Hepatology International

A consensus integrated care pathway for patients with primary biliary cholangitis.

Biliary Endoscopy in the Management of Primary Sclerosing Cholangitis and its Complications

 

Review | Diagnosis and management of cirrhosis and its complications

10 May, 2023 | 16:06h | UTC

Diagnosis and Management of Cirrhosis and Its Complications: A Review – JAMA (free for a limited period)

Author Interview: Management of Cirrhosis in 2023

 

Review | The global burden of liver disease

5 May, 2023 | 15:23h | UTC

The Global Burden of Liver Disease – Clinical Gastroenterology and Hepatology

 

Review | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension

4 May, 2023 | 13:36h | UTC

Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension – Liver International

 

RCT | High vs. low target mean arterial pressure in patients with cirrhosis and septic shock

3 May, 2023 | 15:01h | UTC

A randomized-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock – Journal of Hepatology

 

Review | New treatment paradigms in primary biliary cholangitis

26 Apr, 2023 | 13:49h | UTC

New Treatment Paradigms in Primary Biliary Cholangitis – Clinical Gastroenterology and Hepatology

 

Perspective | Liver transplantation for patients with severe acute on chronic liver failure: it is time to change paradigms

25 Apr, 2023 | 14:37h | UTC

Liver transplantation for patients with severe acute on chronic liver failure: it is time to change paradigms – Intensive Care Medicine

 

Commentary on Twitter

 

RCT | Bariatric–metabolic surgery is more effective than lifestyle intervention plus best medical care in non-alcoholic steatohepatitis

24 Apr, 2023 | 14:03h | UTC

Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial – The Lancet

News Release: Surgery most effective treatment of metabolic liver disease – King’s College London

 

Commentary on Twitter

 

Guideline | Management of psychiatric disorders in patients with hepatic and gastrointestinal diseases

19 Apr, 2023 | 13:07h | UTC

Management of Psychiatric Disorders in Patients with Hepatic and Gastrointestinal Diseases – Indian Journal of Psychiatry

 

Guideline | Intrahepatic cholestasis of pregnancy

18 Apr, 2023 | 13:24h | UTC

Intrahepatic cholestasis of pregnancy – BJOG

 

Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU

17 Apr, 2023 | 13:19h | UTC

Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations – Critical Care Medicine (free for a limited period)

Executive Summary: Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations – Critical Care Medicine (free for a limited period)

 

Review | Anticoagulation in patients with liver cirrhosis: friend or foe?

11 Apr, 2023 | 14:17h | UTC

Anticoagulation in Patients with Liver Cirrhosis: Friend or Foe? – Digestive Diseases and Sciences

 

Review | Assessing the risk of surgery in patients with cirrhosis

10 Apr, 2023 | 13:20h | UTC

Assessing the risk of surgery in patients with cirrhosis – Hepatology Communications

 

Global epidemiology of cirrhosis — Etiology, trends and predictions

6 Apr, 2023 | 13:27h | UTC

Global epidemiology of cirrhosis — aetiology, trends and predictions – Nature Reviews Gastroenterology & Hepatology

 

Commentary on Twitter

 

RCT | Comparable efficacy of cefotaxime, ceftriaxone, and ciprofloxacin in treating spontaneous bacterial peritonitis

3 Apr, 2023 | 14:01h | UTC

Summary: This multicenter, prospective, open-label, randomized controlled trial compared the efficacy of cefotaxime, ceftriaxone, and ciprofloxacin as initial treatments for spontaneous bacterial peritonitis (SBP) in patients with cirrhosis and ascites. The study included 261 patients aged 16 to 75, with liver cirrhosis, ascites, and a polymorphonuclear cell count of >250/mm3. Researchers performed follow-up paracentesis at 48 hours to evaluate the assigned antibiotics, and assessed resolution rates at 120 and 168 hours of treatment.

The primary endpoint, resolution rates at 120 hours, showed no statistically significant difference between the groups: 67.8% for cefotaxime, 77.0% for ceftriaxone, and 73.6% for ciprofloxacin. One-month mortality rates were also similar. The study concluded that these antibiotics are equally effective as initial treatments for SBP, particularly for community-acquired infections, when administered based on response-guided therapy.

Article: Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP – American Journal of Gastroenterology (free for a limited period)

 

Overcoming size disparity in liver transplant access: prioritizing smaller donors for smaller candidates

3 Apr, 2023 | 13:41h | UTC

Association of Body Surface Area With Access to Deceased Donor Liver Transplant and Novel Allocation Policies – JAMA Surgery (free for a limited period)

Invited Commentary: Addressing Size-Based Disparities in Liver Transplant – JAMA Surgery (free for a limited period)

 

Commentary on Twitter

 

RCT | Efficacy and safety of colesevelam for the treatment of bile acid diarrhea

30 Mar, 2023 | 14:06h | UTC

Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Review | Recompensation in cirrhosis: current evidence and future directions

29 Mar, 2023 | 13:24h | UTC

Recompensation in Cirrhosis: Current Evidence and Future Directions – Journal of Clinical and Experimental Hepatology (free for a limited period)

 

Cohort Study | Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated

29 Mar, 2023 | 13:02h | UTC

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated – Journal of Hepatology

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.